{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:42:52Z","timestamp":1791934972324,"version":"4.3.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The benefits of direct oral anticoagulants (DOACs) and warfarin in elderly Japanese patients with non-valvular atrial fibrillation (NVAF) and high home systolic blood pressure (H-SBP) are unclear. This sub-cohort study of the ANAFIE Registry estimated the incidence of clinical outcomes in patients receiving anticoagulant therapy (warfarin and DOACs) stratified by H-SBP levels (&lt;125\u2009mmHg, \u2265125\u2013&lt;135\u2009mmHg, \u2265135\u2013&lt;145\u2009mmHg and \u2265145\u2009mmHg). Of the overall ANAFIE population, 4933 patients who underwent home blood pressure (H-BP) measurements were analyzed; 93% received OACs (DOACs: 3494, 70.8%; warfarin: 1092, 22.1%). In the warfarin group, at &lt;125\u2009mmHg and \u2265145\u2009mmHg, the respective incidence rates (per 100 person-years) were 1.91 and 5.89 for net cardiovascular outcome (a composite of stroke\/systemic embolic events (SEE) and major bleeding), 1.31 and 3.39 for stroke\/SEE, 0.59 and 3.91 for major bleeding, 0.59 and 3.43 for intracranial hemorrhage (ICH), and 4.01 and 6.24 for all-cause death. Corresponding incidence rates in the DOACs group were 1.64 and 2.65, 1.00 and 1.88, 0.78 and 1.69, 0.55 and 1.31, and 3.43 and 3.51. In warfarin-treated patients, the incidence rates of net cardiovascular outcome, stroke\/SEE, major bleeding, and ICH were significantly increased at H-SBP\u2009\u2265\u2009145\u2009mmHg versus &lt;125\u2009mmHg. In the DOAC group, although there was no significant difference between H-SBP\u2009&lt;\u2009125\u2009mmHg and \u2265145\u2009mmHg, the incidence rates of these events tended to increase at \u2265145\u2009mmHg. These results suggest that strict BP control guided by H-BP is required in elderly NVAF patients receiving anticoagulant therapy.<\/jats:p>","DOI":"10.1038\/s41440-023-01361-4","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T11:02:11Z","timestamp":1689073331000},"page":"2575-2582","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Anticoagulant therapy and home blood pressure-associated risk for stroke\/bleeding events in elderly patients with non-valvular atrial fibrillation: the sub-cohort study of ANAFIE registry"],"prefix":"10.1038","volume":"46","author":[{"given":"Kazuomi","family":"Kario","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Hasebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Akao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Atarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Koretsune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tsutsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takenori","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Teramukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Morishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"key":"1361_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/1747493019897870","volume":"16","author":"G Lippi","year":"2021","unstructured":"Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021;16:217\u201321.","journal-title":"Int J Stroke"},{"key":"1361_CR2","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1253\/circj.CJ-20-1212","volume":"86","author":"K Ono","year":"2022","unstructured":"Ono K, Iwasaki YK, Akao M, Ikeda T, Ishii K, Inden Y, et al. JCS\/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. Circ J. 2022;86:1790\u2013924.","journal-title":"Circ J."},{"key":"1361_CR3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/ehjqcco\/qcab025","volume":"8","author":"T Yamashita","year":"2021","unstructured":"Yamashita T, Suzuki S, Inoue H, Akao M, Atarashi H, Ikeda T, et al. Two-year outcomes of more than 30 000 elderly patients with atrial fibrillation: results from the All Nippon AF In the Elderly (ANAFIE) Registry. Eur Heart J Qual Care Clin Outcomes. 2021;8:202\u201313.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"1361_CR4","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1161\/HYPERTENSIONAHA.122.19810","volume":"79","author":"K Kario","year":"2022","unstructured":"Kario K, Hasebe N, Okumura K, Yamashita T, Akao M, Atarashi H, et al. Home blood pressure can predict the risk for stroke\/bleeding events in elderly patients with nonvalvular atrial fibrillation from the ANAFIE Registry. Hypertension. 2022;79:2696\u2013705.","journal-title":"Hypertension."},{"key":"1361_CR5","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.amjcard.2015.07.032","volume":"116","author":"R Nagarakanti","year":"2015","unstructured":"Nagarakanti R, Wallentin L, Noack H, Brueckmann M, Reilly P, Clemens A, et al. Comparison of characteristics and outcomes of dabigatran versus warfarin in hypertensive patients with atrial fibrillation (from the RE-LY Trial). Am J Cardiol. 2015;116:1204\u20139.","journal-title":"Am J Cardiol"},{"key":"1361_CR6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1161\/HYPERTENSIONAHA.119.13138","volume":"74","author":"S Park","year":"2019","unstructured":"Park S, Bergmark BA, Shi M, Lanz HJ, Chung N, Ruff CT, et al. Edoxaban versus warfarin stratified by average blood pressure in 19 679 patients with atrial fibrillation and a history of hypertension in the ENGAGE AF-TIMI 48 Trial. Hypertension. 2019;74:597\u2013605.","journal-title":"Hypertension."},{"key":"1361_CR7","doi-asserted-by":"publisher","first-page":"e002015","DOI":"10.1161\/JAHA.115.002015","volume":"4","author":"MP Rao","year":"2015","unstructured":"Rao MP, Halvorsen S, Wojdyla D, Thomas L, Alexander JH, Hylek EM, et al. Blood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. J Am Heart Assoc. 2015;4:e002015.","journal-title":"J Am Heart Assoc"},{"key":"1361_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ahj.2016.05.001","volume":"178","author":"S Vemulapalli","year":"2016","unstructured":"Vemulapalli S, Hellkamp AS, Jones WS, Piccini JP, Mahaffey KW, Becker RC, et al. Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: results from the ROCKET AF Trial. Am Heart J. 2016;178:74\u201384.","journal-title":"Am Heart J"},{"key":"1361_CR9","unstructured":"Inoue H, Yamashita T, Akao M, Atarashi H, Ikeda T, Okumura K, et al. Prospective observational study in elderly patients with non-valvular atrial fibrillation: rationale and design of the All Nippon AF In the Elderly (ANAFIE) Registry. J Cardiol. 2018; 72: 300\u20136. [Corrigendum in J Cardiol. 2022; 80: 375\u20136.]"},{"key":"1361_CR10","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692\u20134.","journal-title":"J Thromb Haemost"},{"key":"1361_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/jch.14095","volume":"23","author":"K Kario","year":"2021","unstructured":"Kario K, Hasebe N, Okumura K, Yamashita T, Akao M, Atarashi H, et al. High prevalence of masked uncontrolled morning hypertension in elderly non-valvular atrial fibrillation patients: home blood pressure substudy of the ANAFIE Registry. J Clin Hypertens (Greenwich). 2021;23:73\u201382.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1361_CR12","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"1361_CR13","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1161\/STROKEAHA.110.580506","volume":"41","author":"K Toyoda","year":"2010","unstructured":"Toyoda K, Yasaka M, Uchiyama S, Nagao T, Gotoh J, Nagata K, et al. Blood pressure levels and bleeding events during antithrombotic therapy: the Bleeding with Antithrombotic Therapy (BAT) Study. Stroke. 2010;41:1440\u20134.","journal-title":"Stroke."},{"key":"1361_CR14","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/ajh\/hpx094","volume":"30","author":"M Ishii","year":"2017","unstructured":"Ishii M, Ogawa H, Unoki T, An Y, Iguchi M, Masunaga N, et al. Relationship of hypertension and systolic blood pressure with the risk of stroke or bleeding in patients with atrial fibrillation: the Fushimi AF Registry. Am J Hypertens. 2017;30:1073\u201382.","journal-title":"Am J Hypertens"},{"key":"1361_CR15","doi-asserted-by":"publisher","first-page":"e004075","DOI":"10.1161\/JAHA.116.004075","volume":"5","author":"E Kodani","year":"2016","unstructured":"Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Otsuka T, et al. Impact of blood pressure control on thromboembolism and major hemorrhage in patients with nonvalvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry. J Am Heart Assoc. 2016;5:e004075.","journal-title":"J Am Heart Assoc"},{"key":"1361_CR16","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1253\/circj.CJ-14-0720","volume":"78","author":"M Yasaka","year":"2014","unstructured":"Yasaka M, Lip GY. Impact of non-vitamin K antagonist oral anticoagulants on intracranial bleeding in Asian patients with non-valvular atrial fibrillation. Circ J. 2014;78:2367\u201372.","journal-title":"Circ J"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01361-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01361-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01361-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:02:28Z","timestamp":1701734548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01361-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1361"],"URL":"https:\/\/doi.org\/10.1038\/s41440-023-01361-4","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,11]]},"assertion":[{"value":"3 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr KK received research grants from Bristol Myers Squibb, Bayer, Daiichi Sankyo, Omron Healthcare Inc., and A&D Inc, and remuneration from Daiichi Sankyo, Bayer, and Omron Healthcare Inc. Dr NH received research funding from Bristol Myers Squibb and Daiichi Sankyo, and remuneration from Daiichi Sankyo and Bayer. Dr KO received remuneration from Nippon Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, and Medtronic. Dr TY received research funding from Bristol Myers Squibb, Bayer, and Daiichi Sankyo, manuscript fees from Daiichi Sankyo and Bristol Myers Squibb, and remuneration from Daiichi Sankyo, Bayer, Pfizer Japan, and Bristol Myers Squibb. Dr MA received research funding from Bayer and Daiichi Sankyo, and remuneration from Bristol Myers Squibb, Nippon Boehringer Ingelheim, Bayer, and Daiichi Sankyo. Dr HA received remuneration from Daiichi Sankyo. Dr TI received research funding from Daiichi Sankyo and Bayer, and remuneration from Daiichi Sankyo, Bayer, Nippon Boehringer Ingelheim, and Bristol Myers Squibb. Dr YK received remuneration from Daiichi Sankyo, Bayer, and Nippon Boehringer Ingelheim. Dr WS received research funding from Bristol Myers Squibb, Daiichi Sankyo, and Nippon Boehringer Ingelheim, and patent royalties\/licensing fees from Daiichi Sankyo, Pfizer Japan, Bristol Myers Squibb, Bayer, and Nippon Boehringer Ingelheim. Dr SS received research funding from Mitsubishi-Tanabe and Daiichi Sankyo, and remuneration from Bristol Myers Squibb and Daiichi Sankyo. Dr HT received research funding from Daiichi Sankyo and Nippon Boehringer Ingelheim, remuneration from Daiichi Sankyo, Bayer, Nippon Boehringer Ingelheim, and Pfizer Japan, scholarship funding from Daiichi Sankyo, and consultancy fees from Pfizer Japan, Bayer, and Nippon Boehringer Ingelheim. Dr KT received lecture honoraria from Daiichi Sankyo, Otsuka, Novartis, Abbott, Bayer Yakuhin, and Bristol Myers Squibb outside the submitted work. Dr AH participated in a course endowed by Boston Scientific Japan, has received research funding from Daiichi Sankyo and Bayer, and remuneration from Bayer, Daiichi Sankyo, Bristol Myers Squibb, and Nippon Boehringer Ingelheim. Dr MY received research funding from Nippon Boehringer Ingelheim, and remuneration from Nippon Boehringer Ingelheim, Daiichi Sankyo, Bayer, Bristol Myers Squibb, and Pfizer Japan. Dr TY acted as an Advisory Board member of Daiichi Sankyo and received remuneration from Daiichi Sankyo and Bristol Myers Squibb. Dr ST received research funding from Nippon Boehringer Ingelheim and remuneration from Daiichi Sankyo, Sanofi, Takeda, Chugai Pharmaceutical, Solasia Pharma, Bayer, Sysmex, Nipro, NapaJen Pharma, Gunze, Kaneka, Kringle Pharma and Atworking. TK, Dr YM, and AT are employees of Daiichi Sankyo. Dr HI received remuneration from Daiichi Sankyo, Bristol Myers Squibb, and Nippon Boehringer Ingelheim.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}